सभी अध्ययन
सक्रिय लेकिन भर्ती नहींचरण 2हस्तक्षेपात्मक

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

The MoonStone study is testing a new medicine called obexelimab for people living with relapsing multiple sclerosis (MS). MS is a long-term condition affecting the brain and spinal cord, causing a wide range of symptoms. This study wants to find out how well obexelimab works and if it's safe to use. For the first 12 weeks, some participants will receive obexelimab, while others will get a placebo (a dummy treatment). After this, for the next 12 weeks, everyone will receive obexelimab. Following this, participants will continue to receive obexelimab for a longer period. This research is important to potentially offer new treatment options for people with relapsing MS, aiming to reduce relapses and improve quality of life.

एक नजर में

स्थिति
सक्रिय लेकिन भर्ती नहीं
चरण
चरण 2
प्रायोजक
Zenas BioPharma (USA), LLC
नामांकन लक्ष्य
93
प्रारंभ
26 Aug 2024
अनुमानित पूर्णता
01 फरवरी 2026

यह अध्ययन किस बारे में है?

This study, called MoonStone, is looking into a new medicine known as obexelimab for people who have relapsing multiple sclerosis (MS). Relapsing MS is a type of MS where you have periods of new or worsening symptoms (relapses) followed by periods of recovery. The main goal of this study is to see if obexelimab is effective at managing MS and if it's safe for people to use.

For the first part of the study, lasting 12 weeks, some participants will receive obexelimab, while others will be given a placebo. A placebo is a treatment that looks just like the real medicine but contains no active drug. This helps researchers understand if any improvements are due to obexelimab itself. After these 12 weeks, everyone in the study will receive obexelimab for a further 12 weeks, and then for an even longer period of about a year.

Finding new and effective treatments for MS is really important. Studies like MoonStone help doctors and researchers understand how new medicines work, their potential benefits, and any side effects. This research could ultimately lead to more options for people with relapsing MS, helping to manage their condition and improve their daily lives.

मुख्य निष्कर्ष

  • MoonStone is a study for people with relapsing multiple sclerosis.
  • It's testing a new medicine called obexelimab.
  • Participants will receive weekly injections, either obexelimab or a placebo at first, then all obexelimab.
  • The study lasts about 1 year and 9 months, including regular clinic visits.
  • It's about finding new and safer ways to treat MS.

कौन पात्र हो सकता है?

To join this study, you need to be an adult between 18 and 60 years old and have been diagnosed with a type of MS called relapsing MS (this includes relapsing-remitting MS or secondary progressive MS with relapses).

Your MS should show some signs of recent activity. This means you would have had at least one relapse in the last year, or two relapses in the last two years, or have shown recent signs of MS activity on a brain scan (MRI) within the last six months. Also, your MS should not be too severe, meaning your disability score (known as EDSS) should be 5.5 or less.

There are also some reasons why you might not be able to join. For example, if you have primary progressive MS or secondary progressive MS without relapses, or if you have a different condition called neuromyelitis optica spectrum disorder. If you've had a relapse very recently (within the last 30 days) or have a very large number of active lesions on your MRI scan, you also wouldn't be able to take part.

क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?

यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.

  1. क्या आपकी उम्र 18 से 60 वर्ष के बीच है?
  2. Do you have a diagnosis of relapsing MS (relapsing-remitting or secondary progressive with relapses)?
  3. Have you had at least one relapse in the last year, two in the last two years, or an active lesion on a recent MRI scan?
  4. Is your disability from MS not too severe (EDSS score 5.5 or less)?
  5. Do you not have primary progressive MS or secondary progressive MS without relapses?
अपने परिणाम देखने के लिए हर प्रश्न का उत्तर दें।.

भागीदारी में क्या शामिल है?

If you decide to take part in the study, it will involve several stages over about 92 weeks (approximately 1 year and 9 months). First, there's a screening period to check if the study is right for you.

For the first 12 weeks, you'll receive weekly injections under the skin (like a small jab) of either obexelimab or a placebo. You won't know which one you're getting. After this, for the next 12 weeks, every participant will receive weekly injections of obexelimab. Following these 24 weeks, you'll continue to receive obexelimab for about a year.

Throughout the study, you'll have regular visits to the clinic for check-ups, assessments, and to receive your medication. There will also be a follow-up period after your last dose of medicine to monitor your health. You may need to visit the clinic more often during this follow-up if special blood tests haven't returned to normal levels. The study team will explain everything in detail if you are interested.

संभावित जोखिम और लाभ

Participating in a clinical trial may offer potential benefits, such as access to a new treatment before it's widely available and closer monitoring of your health during the study. However, there are also potential risks involved. The new medicine, obexelimab, might have side effects, some of which may not be fully known yet. You might also receive a placebo, meaning you wouldn't be getting the active medicine for a period. Your doctors and the study team will discuss all known risks with you in detail. Remember, deciding whether to join is completely up to you, and you have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (47)

  • North Central Neurology
    सत्यापित पोस्टकोड
    Cullman, United States
  • Center for Neurology and Spine
    सत्यापित पोस्टकोड
    फीनिक्स, संयुक्त राज्य अमेरिका
  • Perseverance Research Center
    सत्यापित पोस्टकोड
    स्कॉट्सडेल, संयुक्त राज्य अमेरिका
  • Regina Berkovich MD PhD, Inc
    सत्यापित पोस्टकोड
    वेस्ट हॉलीवुड, संयुक्त राज्य अमेरिका
  • Aqualine Clinical Research
    सत्यापित पोस्टकोड
    नेपल्स, संयुक्त राज्य अमेरिका
  • University of South Florida
    सत्यापित पोस्टकोड
    टाम्पा, संयुक्त राज्य अमेरिका
  • University of Massachusetts Medical School
    सत्यापित पोस्टकोड
    Worcester, United States
  • Infusion Associates Plymouth
    सत्यापित पोस्टकोड
    Plymouth, United States
  • MS Center for Innovations in Care
    सत्यापित पोस्टकोड
    सेंट लुइस, संयुक्त राज्य अमेरिका
  • Holy Name Medical Center
    सत्यापित पोस्टकोड
    Teaneck, United States
  • Boster Center for MS
    सत्यापित पोस्टकोड
    कोलंबस, संयुक्त राज्य अमेरिका
  • North Texas Institute of Neurology and Headache
    सत्यापित पोस्टकोड
    Plano, United States

सामान्य प्रश्न

What is multiple sclerosis (MS)?

MS is a long-term condition that affects your brain and spinal cord, which can lead to problems with vision, balance, movement, and sensation. Relapsing MS means symptoms come and go.

What is obexelimab?

Obexelimab is a new medicine being tested in this study to see if it can help people with relapsing MS.

प्लेसबो क्या है?

A placebo is a 'dummy' treatment that looks like the real medicine but doesn't contain any active drug. It helps researchers compare the new medicine's effects.

दवा कैसे दी जाएगी?

The medicine (obexelimab or placebo) will be given as a weekly injection under the skin.

अध्ययन कितने समय तक चलेगा?

The study is expected to last for about 92 weeks, which is roughly 1 year and 9 months.

और अधिक जानने के लिए कैसे पता करें

किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.

चर्चा

समुदाय चर्चा

हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.